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Abstract 
Lipodystrophy is a rare condition which can 
be inherited or acquired, localised or generalised. It 
is characterised by abnormal adipose tissue 
distribution and in some cases underlying metabolic 
derangement, including diabetes mellitus, 
hypertriglyceridemia, hepatic steatosis, polycystic 
ovaries and acanthosis nigricans. Today, most cases 
of lipodystrophy are associated with human 
immunodeficiency virus (HIV).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This article gives a review of the possible 
mechanisms associated with HIV lipodystrophy, 
namely HIV infection itself, genetic susceptibility 
to HIV lipodystrophy and effects of treatment with 
highly active antiretroviral therapy (HAART). 
Treating HIV lipodystrophy is challenging. The 
various treatment options currently available for 
treating lipodystrophy are reviewed. 
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Introduction 
Lipodystrophy is a rare disorder. In recent 
years it is most often seen in association with 
human immunodeficiency virus (HIV). Recognising 
this syndrome is of importance because it has a 
psychological impact due to body shape changes 
and also because of the underlying metabolic 
abnormalities, which are linked with increased 
morbidity and mortality. 
Lipodystrophy is characterised by generalised 
or partial loss of adipose tissue.  There are different 
extents of adipose tissue loss, with some having 
loss from discrete areas (localised lipodystrophy), 
others from the limbs (partial lipodystrophy) whilst 
others having loss from most of the body 
(generalised lipodystrophy).1 In localised 
lipodystrophy, usually there are only cosmetic 
implications. However, in the partial and 
generalised forms, an association with severe 
metabolic derangement exists, including diabetes 
mellitus, hypertriglyceridemia, hepatic steatosis, 
polycystic ovaries and acanthosis nigricans.  
Lipodystrophy can be inherited 
(monogenetic), or acquired (autoimmune or 
idiopathic), in patients who do not have a clear 
inheritance pattern. Therefore lipodystrophy can be 
classified into the following 4 main categories: 
congenital generalised lipodystrophy (CGL), 
familial partial lipodystrophy (FPL), acquired 
generalised lipodystrophy (AGL) and acquired 
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partial lipodystrophy (APL). Lipodystrophy in 
patients receiving highly active antiretroviral 
therapy (HAART) has become the most common 
form of lipodystrophy .1-2  
 
Presentation and diagnosis 
HIV-associated lipodystrophy refers to both 
lipohypertrophy, where there is abnormal fat 
accumulation usually in the dorsocervical fat pad, 
neck, breasts and around abdominal viscera 3, and 
lipoatrophy with loss of subcutaneous fat around 
the face, arms, legs and buttocks. Facial fat loss can 
be very severe and psychologically disturbing to 
patients, as it carries a social stigma. This may limit 
compliance to HAART. In fact lipodystrophy has 
also been associated with lower reported quality of 
life.4 Patients report reduced satisfaction with their 
body image, self-esteem, problems with social 
relationships, less confidence about their health and 
embarrassment due to body changes.  Many patients 
also develop hypertriglyceridemia and some also 
develop impaired glucose tolerance and insulin 
resistance.1 
The diagnosis is mainly clinical, but 
additional tests for glucose intolerance, serum 
lipids, liver function and hyperuricaemia are 
indicated.1 Some tools that are used to help make a 
diagnosis are: anthropometry, bioelectrical 
impedance analysis (BIA), imaging techniques such 
as dual-energy X-ray absorptiometry (DEXA), 
magnetic resonance imaging (MRI) and computed 
tomography (CT).  Both CT and MRI demonstrate 
accumulation of intra abdominal visceral fat and 
minimal subcutaneous fat.3,5-6 
 
Pathogenesis 
Lipodystrophy has a multi-factorial aetiology, 
including HIV infection itself, genetic susceptibility 
and effects of HAART. HIV infection itself may 
contribute to fat redistribution by infecting 
macrophages in adipose tissue, which release pro-
inflammatory cytokines and enhance local 
inflammation.7 This is supported by increased 
tumour necrosis factor-alpha (TNF-α) expression 
observed in HAART-naive HIV-infected patients, a 
pro-inflammatory cytokine that initiates adipocyte 
apoptosis.2,7.In a study by Castilhos et al8 genetic 
variability in the adiponectin receptor, which is a 
circulating petptide secreted by mature adipocytes 
that acts as a regulator of glucose and lipid 
metabolism, appears to be associated with different 
anthropometric and metabolic phenotypes in HIV 
infected patients on HAART. 
HIV type 1 (HIV-1) protease inhibitors (PI) 
are a class of drugs used in HIV9. They inhibit viral 
replication by selectively binding to viral proteases, 
therefore blocking proteolytic cleavage of protein 
precursors necessary for the production of 
infectious viral particles. Nucleoside reverse 
transcriptase inhibitors (NRTIs), another class of 
drugs used in patients infected with HIV9, block the 
reverse transcriptase enzyme, which controls the 
replication of HIV genetic material. Both these 
drugs are particularly implicated in HAART-
induced lipodystrophy.  
One mechanism thought to be implicated in 
the pathogenesis of PI-induced lipodystrophy is the 
down-regulation of peroxisome proliferator-
activated receptor gamma (PPAR-ϒ), (a nuclear-
receptor which regulates adipocyte differentiation 
and maintenance) by the up-regulation of the 
Wingless-related integration site (wnt)/β-catenin 
signalling pathway.10 One of the functions of this 
pathway is to inhibit adipogenic gene expression.11  
Another effect of PI is the down-regulation of 
essential adipogenesis transcription factors like 
CCAAT-enhancer-binding proteins (C/EBP)-α, 
which have major adipogenic function.9 This down-
regulation creates reactive oxygen species, which 
may induce insulin resistance by inhibiting glucose 
transporter 4 (GLUT-4), together with impaired 
leptin and adiponectin production. PIs share similar 
sequence homology with 2 proteins involved in 
lipid metabolism, namely cytoplasmic retinoic acid-
binding protein type 1 (CRABP-1) and low-density 
lipoprotein receptor-related protein (LDLR-RP). 
Inhibition of the former leads to decreased fat 
storage and adipocyte apoptosis with subsequent 
release of lipids into the blood and the latter induces 
hyperlipidaemia by inhibiting hepatic and 
endothelial removal of chylomicrons and 
triglycerides from the circulation.12-14 
NRTIs, especially zidovudine and stavudine, 
are thought to inhibit mitochondrial polymerase-ϒ 
and cause mitochondrial dysfunction, ultimately 
leading to apoptosis and loss of fat cells. This in 
turn causes insulin resistance and secondary 
dyslipidaemia.6,15 
Since PI and NRTI are usually prescribed 
simultaneously, it is difficult to predict which drug 
is responsible for which phenotypic appearance, 
although it is likely that PI induce peripheral 
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lipoatrophy and metabolic abnormalities whereas 
NRTIs may be responsible for the lipohypertrophy 
with accumulation of fat in the neck region.1 Newer 
HIV drugs are less likely to cause the condition: old 
NRTIs such as zalcitabine, didanosin, stavudine and 
zidovudine are more prone to lipodystrophy than 
the newer NRTIs lamivudine, abacavir and 
tenofovir.6,16 The older agents have been phased out 
in most developed countries but are still in use in 
low-resource settings. 
 
Epidemiology 
The global prevalence of lipodystrophy 
among HIV patients ranges considerably and 
studies quote very differing rates (1-84%).6 Gender 
influences mode of presentation: women tend to be 
more likely to report fat accumulation in the 
abdomen and breasts, whereas men are more likely 
to notice the loss of fat from the face and other 
extremities.17 
Risk factors for HIV-induced lipodystrophy 
include the duration of antiretroviral therapy 
(particularly receiving treatment for 2 years or 
more), female sex, obesity, higher triglyceride level, 
white race, older age and low CD4 count.18 
 
Management  
Treatment can be challenging. First and 
foremost, it should be targeted at managing the 
underlying metabolic derangements of glucose and 
lipids aggressively.1 Diet and exercise have been 
proven to improve insulin sensitivity but no 
controlled clinical trials have been conducted to 
guide treatment for the metabolic complications in 
patients with lipodystrophy.  
Management of severe lipodystrophy needs to 
involve modifying the treatment regimen, especially 
if an older drug is being administered. If this is not 
possible, using a lower dose of the drug will need to 
be considered. In a meta-analysis of trials 
comparing doses of stavudine which is an older 
NRTI (40mg vs 30mg) in high income countries, 
there was strong evidence that the lower 30 mg dose 
of stavudine was associated with lower rates of 
side-effects including lipodystrophy, and similar 
efficacy in suppressing HIV viral load, compared to 
the 40 mg dose.19 These findings informed the 
WHO recommendations for lower dose stavudine in 
2007 and the subsequent discontinuation of 
stavudine due to severe side-effects in 2009.20  In a 
study HIV-infected adults were switched from 
stavudine/didanosine to the newer agents 
tenofovir/lamivudine. There was an increase in limb 
fat mass and total fat mass, as measured by DEXA 
48 weeks after the regimen change.21 Thus the 
newer NRTI agents are recommended. 
No controlled clinical trials have been 
conducted to guide drug therapy for metabolic 
complications. For severe hypertriglyceridemia, 
fibrates and fish oil should be used and may be 
combined with a statin.1   Metformin remains the 
first-line treatment for diabetes and insulin 
resistance, when tolerated. Studies of 
thiazolidinedione treatment for HIV lipodystrophy 
have shown conflicting results. A meta-analysis has 
shown that pioglitazone may be safer than 
rosiglitazone but any benefits on improved fat 
deposition in lipodystrophic regions were small.22   
In many patients with diabetes, insulin therapy is 
needed and since patients usually require high doses 
of insulin, highly concentrated insulin such as U-
500 insulin  should be used, due to the difficulty in 
injecting a large volume of insulin whilst having no 
subcutaneous fat in the abdomen or thighs. GLP-1 
analogues may also be considered in selected 
patients.23 
Tesamorelin, a synthetic form of growth 
hormone-releasing hormone, which was approved 
by the Food and Drug Administration (FDA) in 
2010, seems to have some role in decreasing 
visceral adipose tissue.24-25 
Leptin therapy (Metreleptin) was approved by 
the FDA in 2014 for treating generalised 
lipodystrophy with or without metabolic 
complications but not associated with HIV.26-27 In 
patients with lipodystrophy a state of leptin 
deficiency occurs due to lack of adipocytes. Leptin 
regulates appetite by allowing negative feedback 
via the hypothalamus. Patients with leptin 
deficiency lose this regulation causing hyperphagia.  
However due to the lack of adipocytes, which 
usually store the excess food ingested, this fat is 
deposited in abnormal places, leading to the typical 
appearance in patients with lipodystrophy. Leptin 
therapy was found to improve the overall clinical 
picture of the metabolic syndrome; namely the 
hyperglycaemia and insulin resistance, the 
hyperlipidaemia and hepatosteatosis.  
Plastic surgery procedures, namely liposuction 
and lipectomy did not yield very positive cosmetic 
results, as lipohypertrophy usually recurs. For 
lipoatrophy, free flaps, lipotransfer (transplantation 
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of fat harvested during liposuction of the 
dorsocervical fat pad), and commercial fillers such 
as Poly-L-lactic acid (Sculptra®) have been 
approved by the FDA as treatment for facial 
lipoatrophy in HIV-positive patients.3,28 
In addition to the physical consequences of 
lipodystrophy, an important component to clinical 
management is the evaluation of the impact of 
lipodystrophy on emotional well-being and quality 
of life.4 
 
Prognosis 
There might be some regression of HIV-
associated lipodystrophy on stopping the implicated 
PI or NRTI therapy. To date, there has been no 
studies determining the morbidity and mortality 
from the body morphologic changes of HIV 
associated lipodystrophy per se. However the 
excess morbidity and mortality is attributed to 
atherosclerotic cardiovascular disease secondary to 
insulin resistance, hyperglycaemia and 
hyperlipidaemia. 
 
Conclusion 
HAART is the gold standard treatment for 
HIV/AIDS care and treatment, however adverse 
treatment related outcomes, including lipodystrophy 
are relatively more common in low and middle-
income counties, due to the use of older drugs. This 
has considerable implications in view of the 
increased risk of metabolic disease, quality of life 
and drug adherence. With early detection of HIV 
and longer lifespans of infected individuals, the 
length of HAART exposure and the burden of 
related metabolic complications are also expected to 
rise. More evidence based interventional studies are 
needed in this respect to reduce the burden of HIV 
and lipodystrophy. 
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